Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAMUSCULARGeneric

NALTREXONE

NALTREXONE

Standard Dose
380MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview NALTREXONE is listed in Drugs@FDA under application 213195 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient NALTREXONE Form and strength FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 380MG/VIAL Sponsor TEVA PHARMS USA INC Submission history Latest submission status date: 2023-07-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview NALTREXONE is listed in Drugs@FDA under application 213195 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient NALTREXONE Form and strength FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 380MG/VIAL Sponsor TEVA PHARMS USA INC Submission history Latest submission status date: 2023-07-06 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
NALTREXONE (NALTREXONE) | Drug Monograph | MedicHelpline